VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Acknowledging her efforts keeps her feelings from getting hurt, and being honest about what you can and can’t offer right now ...

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised multidisciplinary treatments, at a cost.

A small Italian study has found an Ozempic-style drug can halve the number of migraine days suffered in a month.